DarioHealth (NASDAQ:DRIO) Issues Quarterly Earnings Results

DarioHealth (NASDAQ:DRIO) released its quarterly earnings results on Tuesday. The company reported ($0.85) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.22) by $0.37, FiscalAI reports. DarioHealth had a negative net margin of 169.87% and a negative return on equity of 52.14%. The firm had revenue of $5.18 million during the quarter, compared to analyst estimates of $5.92 million.

Here are the key takeaways from DarioHealth’s conference call:

• Revenue declined to $5.2 million from $5.6 million in Q1 and $5.4 million a year ago, reflecting implementation timing and the company’s exit from pharmaceutical-services revenue. Management expects momentum to improve in Q3 and Q4, but most contracted revenue is not expected to contribute until 2027.
• DarioHealth ended Q2 with approximately $13.1 million in contracted and late-stage annual recurring revenue, more than 80% of it multi-condition, and reported over 180 signed employer and health-plan accounts. About 75% of new accounts now come through channel partners, which management says is reducing customer-acquisition costs and sales-cycle times.
• Financial efficiency improved, with gross margin rising to 62%, operating expenses falling 21% year over year, and net loss improving 39% to $7.9 million. Management expects incremental revenue from existing implementations, AI-enabled engagement, and new care offerings to generate meaningful operating leverage.
• The company launched an integrated GLP-1 program and introduced women’s health and sleep programs, expanding its provider-backed care and multi-condition platform. Dario expects DarioIQ to increase recurring revenue from existing customers by approximately 10%–15% over time through improved engagement, retention, and outcomes.
• Pro forma cash increased to $36.8 million following a July registered-direct financing, providing additional runway to execute on commercial opportunities and pursue the company’s path toward cash-flow positivity.

DarioHealth Stock Up 1.8%

Shares of DRIO stock traded up $0.13 on Thursday, reaching $7.61. 4,389 shares of the company were exchanged, compared to its average volume of 15,235. The company has a debt-to-equity ratio of 0.50, a current ratio of 3.07 and a quick ratio of 2.62. DarioHealth has a one year low of $5.84 and a one year high of $17.74. The company has a 50-day moving average of $7.10 and a 200-day moving average of $8.27. The company has a market cap of $55.88 million, a price-to-earnings ratio of -1.24 and a beta of 1.11.

Analyst Upgrades and Downgrades

DRIO has been the subject of several recent analyst reports. Stifel Nicolaus reiterated a “buy” rating and set a $10.00 price objective on shares of DarioHealth in a research report on Thursday, May 14th. TD Cowen cut their price target on shares of DarioHealth from $11.00 to $8.00 and set a “hold” rating on the stock in a research report on Wednesday. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of DarioHealth in a report on Friday, July 10th. One analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, DarioHealth has an average rating of “Hold” and an average price target of $9.00.

Insider Activity at DarioHealth

In other news, Director Dennis Matheis bought 14,430 shares of the stock in a transaction dated Thursday, July 23rd. The shares were bought at an average cost of $6.93 per share, with a total value of $99,999.90. Following the completion of the transaction, the director directly owned 43,026 shares of the company’s stock, valued at $298,170.18. This trade represents a 50.46% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 3.50% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the business. Geode Capital Management LLC grew its holdings in shares of DarioHealth by 167.9% during the fourth quarter. Geode Capital Management LLC now owns 49,567 shares of the company’s stock valued at $564,000 after buying an additional 31,063 shares during the last quarter. XTX Topco Ltd lifted its position in DarioHealth by 229.0% in the 2nd quarter. XTX Topco Ltd now owns 62,511 shares of the company’s stock valued at $42,000 after acquiring an additional 43,513 shares in the last quarter. Finally, Kestra Advisory Services LLC acquired a new position in DarioHealth during the 4th quarter valued at about $35,000. Institutional investors and hedge funds own 33.39% of the company’s stock.

About DarioHealth

DarioHealth (NASDAQ:DRIO) is a digital health company specializing in chronic disease management through a smartphone-based care platform. Its core solution combines connected devices—such as glucose meters, blood pressure monitors and smart scales—with real-time data analytics and personalized coaching. The platform is designed to support individuals living with diabetes, hypertension, weight management challenges and other cardiometabolic conditions, offering continuous monitoring, tailored insights and behavioral nudges aimed at improving clinical outcomes.

The Dario platform integrates artificial intelligence and machine learning to deliver personalized guidance and education.